◆英語タイトル:Biocad - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11166
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ロシア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Biocad is a biotechnology company that conducts research and development services. The company develops, manufactures and distributes generic pharmaceutical products. It develops products in urology, gynecology, dermatology, oncology, hematology, autoimmune diseases and infectious diseases therapeutic areas. BIOCAD also carries out clinical trials through laboratories and equipment including department of biochemistry; department of pre-clinical studies; laboratory of molecular genetics; laboratory of genetics recombinant producers; laboratory of antibodies engineering; laboratory of cell engineering and physiology laboratory of recombinant producents. The company offers medicines for complex health conditions such as cancer, HIV and Hepatitis C infections, multiple sclerosis and other disorders. Its products are developed through its own research and development center. The company also operates in India, Belarus, Ukraine, South Africa, Argentina and Brazil. BIOCAD is headquartered in Saint Petersburg, Russia.
Biocad – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Biocad, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Biocad, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Biocad, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Biocad, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Biocad, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Biocad, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Biocad and Shanghai Pharma to Form Joint Venture 10
Licensing Agreements 11
Pfizer Enters Into Licensing Agreement With Biocad For Hemophilia Drug 11
Acquisition 12
Pharmstandard Completes Acquisition of 20% Stake in Biocad 12
Millhouse Completes Acquisition of 50% Stake in Biocad 13
Biocad Rumored To Sell Itself For Up To US$1 Billion 14
Biocad – Key Competitors 15
Biocad – Key Employees 16
Biocad – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Strategy And Business Planning 18
May 23, 2017: Russian Biotechnology Company BIOCAD to Open a Production Facility in Turku 18
Product News 19
Dec 08, 2017: BIOCAD Demonstrated the Use of Hela Cells in Oncology Research 19
Oct 30, 2017: Russian biotechnology company BIOCAD prepares to enter the European market 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21
List of Tables
Biocad, Pharmaceuticals & Healthcare, Key Facts 2
Biocad, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Biocad, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Biocad, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Biocad, Deals By Therapy Area, 2012 to YTD 2018 8
Biocad, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Biocad and Shanghai Pharma to Form Joint Venture 10
Pfizer Enters Into Licensing Agreement With Biocad For Hemophilia Drug 11
Pharmstandard Completes Acquisition of 20% Stake in Biocad 12
Millhouse Completes Acquisition of 50% Stake in Biocad 13
Biocad Rumored To Sell Itself For Up To US$1 Billion 14
Biocad, Key Competitors 15
Biocad, Key Employees 16
Biocad, Other Locations 17
Biocad, Subsidiaries 17
List of Figures
Biocad, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Biocad, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Biocad, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Biocad, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Biocad, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Biocad, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Biocad, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Biocad, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8